Jones LA - Search Results

1

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.

Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, et al. Slamon DJ, et al. Among authors: jones la. Science. 1989 May 12;244(4905):707-12. doi: 10.1126/science.2470152. Science. 1989. PMID: 2470152

2

HER-2/neu oncogene amplification and expression in breast and ovarian cancers.

Press MF, Jones LA, Godolphin W, Edwards CL, Slamon DJ. Press MF, et al. Among authors: jones la. Prog Clin Biol Res. 1990;354A:209-21. Prog Clin Biol Res. 1990. PMID: 1978943 Review. No abstract available.

3

Amplification and overexpression of HER-2/neu (c-erbB2) in endometrial cancers: correlation with overall survival.

Saffari B, Jones LA, el-Naggar A, Felix JC, George J, Press MF. Saffari B, et al. Among authors: jones la. Cancer Res. 1995 Dec 1;55(23):5693-8. Cancer Res. 1995. PMID: 7585656

4

Dietary fiber, Hispanics, and breast cancer risk?

Jones LA, Gonzalez R, Pillow PC, Gomez-Garza SA, Foreman CJ, Chilton JA, Linares A, Yick J, Badrei M, Hajek RA. Jones LA, et al. Ann N Y Acad Sci. 1997 Dec 26;837:524-36. doi: 10.1111/j.1749-6632.1997.tb56897.x. Ann N Y Acad Sci. 1997. PMID: 9472361

5

Chicken ovalbumin upstream promoter transcription factor (COUP-TF): an orphan steroid receptor with a specific pattern of differential expression in human ovarian cancer cell lines.

Kieback DG, Runnebaum IB, Moebus VJ, Kreienberg R, McCamant SK, Edwards CL, Jones LA, Tsai MJ, O'Malley BW. Kieback DG, et al. Among authors: jones la. Gynecol Oncol. 1993 Nov;51(2):167-70. doi: 10.1006/gyno.1993.1266. Gynecol Oncol. 1993. PMID: 7903949

6

Alteration of proto-oncogene c-fos expression in neonatal estrogenized BALB/c female mice & murine cervicovaginal tumor LJ6195.

Scrocchi LA, Jones LA. Scrocchi LA, et al. Among authors: jones la. Endocrinology. 1991 Oct;129(4):2251-3. doi: 10.1210/endo-129-4-2251. Endocrinology. 1991. PMID: 1915105

7

Prognostic significance of estrogen receptor expression in ovarian cancer. Immunoreactive Score (IRS) vs. Composition Adjusted Receptor Level (CARL).

Kieback DG, Press MF, Atkinson EN, Edwards GL, Möbus VJ, Runnebaum IB, Kreienberg R, Jones LA. Kieback DG, et al. Among authors: jones la. Anticancer Res. 1993 Nov-Dec;13(6B):2489-96. Anticancer Res. 1993. PMID: 8135488

8

Improved prediction of survival in advanced adenocarcinoma of the ovary by immunocytochemical analysis and the composition adjusted receptor level of the estrogen receptor.

Kieback DG, McCamant SK, Press MF, Atkinson EN, Gallager HS, Edwards CL, Hajek RA, Jones LA. Kieback DG, et al. Among authors: jones la. Cancer Res. 1993 Nov 1;53(21):5188-92. Cancer Res. 1993. PMID: 8221656

9

Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer.

Reles A, Wen WH, Schmider A, Gee C, Runnebaum IB, Kilian U, Jones LA, El-Naggar A, Minguillon C, Schönborn I, Reich O, Kreienberg R, Lichtenegger W, Press MF. Reles A, et al. Among authors: jones la. Clin Cancer Res. 2001 Oct;7(10):2984-97. Clin Cancer Res. 2001. PMID: 11595686

10

Bioavailability of estradiol as a marker for breast cancer risk assessment.

Jones LA, Ota DM, Jackson GA, Jackson PM, Kemp K, Anderson DE, McCamant SK, Bauman DH. Jones LA, et al. Cancer Res. 1987 Oct 1;47(19):5224-9. Cancer Res. 1987. PMID: 3621208

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

674 results

Search Page

Filters